US 11,739,074 B2
Ras inhibitors
James Aggen, Burlingame, CA (US); G. Leslie Burnett, Redwood City, CA (US); Jennifer Pitzen, Fremont, CA (US); Adrian L. Gill, Atherton, CA (US); Elena S. Koltun, Foster City, CA (US); James Cregg, Belmont, CA (US); Andreas Buckl, San Francisco, CA (US); Anne V. Edwards, San Mateo, CA (US); and John E. Knox, Emerald Hills, CA (US)
Assigned to Revolution Medicines, Inc., Redwood City, CA (US)
Filed by Revolution Medicines, Inc., Redwood City, CA (US)
Filed on Nov. 4, 2020, as Appl. No. 17/88,848.
Claims priority of provisional application 63/043,523, filed on Jun. 24, 2020.
Claims priority of provisional application 63/000,355, filed on Mar. 26, 2020.
Claims priority of provisional application 62/951,562, filed on Dec. 20, 2019.
Claims priority of provisional application 62/930,406, filed on Nov. 4, 2019.
Prior Publication US 2021/0130326 A1, May 6, 2021
Int. Cl. C07D 487/04 (2006.01); C07D 487/10 (2006.01); C07D 513/14 (2006.01); C07D 401/14 (2006.01); A61P 35/00 (2006.01)
CPC C07D 401/14 (2013.01) [A61P 35/00 (2018.01); C07D 487/04 (2013.01); C07D 487/10 (2013.01); C07D 513/14 (2013.01)] 2 Claims
 
1. A compound, or a pharmaceutically acceptable salt thereof, selected from the group consisting of

OG Complex Work Unit Chemistry

OG Complex Work Unit Chemistry

OG Complex Work Unit Chemistry

OG Complex Work Unit Chemistry

OG Complex Work Unit Chemistry